Preoperative Immunotherapy Halts Bowel Cancer for Three Years

A clinical trial has shown that administering immunotherapy before surgery can lead to durable responses in patients with locally advanced bowel cancer, with some individuals remaining free of disease progression for three years or more.

The findings come from a phase 2 study presented at a recent oncology conference and reported by News-Medical, which detailed how preoperative treatment with a combination of immunotherapy drugs resulted in significant tumor shrinkage and, in some cases, complete disappearance of cancer prior to surgery.

Trial Design and Key Outcomes

The trial, conducted at multiple cancer centers in the United Kingdom, enrolled patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer — a subset of bowel cancer known to respond particularly well to immunotherapy. Participants received neoadjuvant treatment with dostarlimab, a programmed death-1 (PD-1) inhibitor, every three weeks for six months before undergoing surgical resection.

Durable Responses Observed

Results showed that over half of the patients achieved a complete pathologic response, meaning no viable cancer cells were found in the tissue removed during surgery. Notably, among those who had a complete response and did not proceed to immediate surgery — instead opting for a watch-and-wait approach — disease-free survival extended beyond three years in several cases, with no signs of recurrence during follow-up.

Implications for Treatment Approach

These findings support a growing body of evidence suggesting that immunotherapy alone may be sufficient to treat certain subtypes of rectal cancer, potentially sparing patients from the lifelong side effects of surgery, chemotherapy, and radiation, such as bowel dysfunction, infertility, and increased risk of secondary cancers.

Context in Bowel Cancer Treatment

Bowel cancer, also known as colorectal cancer, remains one of the most common cancers worldwide. Standard treatment for locally advanced disease typically involves a combination of chemotherapy, radiation, and surgery — an approach that can be effective but often comes with significant short- and long-term morbidity.

Limitations and Ongoing Research

Researchers caution that the current trial was small and focused on a specific molecular subtype of bowel cancer — dMMR/MSI-H tumors — which account for only about 5–10% of all colorectal cancers. The approach may not be effective in patients with proficient mismatch repair (pMMR) tumors, which do not respond as strongly to immunotherapy alone.

Larger, randomized phase 3 trials are now underway to confirm these findings and determine whether preoperative immunotherapy can become a standard option for eligible patients. Scientists are also exploring biomarkers that could help identify which individuals are most likely to benefit from immunotherapy-based strategies.

Conclusion

While immunotherapy is not yet a replacement for standard care in all bowel cancer cases, the durable responses observed in this trial highlight its potential to transform treatment for a defined group of patients. As research continues, the goal is to personalize therapy based on tumor biology, maximizing effectiveness while minimizing unnecessary treatment and its associated burdens.